No headlines found.
Adaptive Announces IVDR Certification for clonoSEQ in European Union
Globe Newswire (Thu, 29-Aug 7:30 AM ET)
Globe Newswire (Thu, 22-Aug 4:03 PM ET)
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
Globe Newswire (Thu, 1-Aug 4:05 PM ET)
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
Globe Newswire (Thu, 11-Jul 4:05 PM ET)
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Adaptive Biotechnologies trades on the NASDAQ stock market under the symbol ADPT.
As of September 16, 2024, ADPT stock price declined to $4.51 with 379,588 million shares trading.
ADPT has a beta of 2.18, meaning it tends to be more sensitive to market movements. ADPT has a correlation of 0.14 to the broad based SPY ETF.
ADPT has a market cap of $664.63 million. This is considered a Small Cap stock.
Last quarter Adaptive Biotechnologies reported $43 million in Revenue and -$.31 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.02.
In the last 3 years, ADPT stock traded as high as $39.79 and as low as $2.28.
The top ETF exchange traded funds that ADPT belongs to (by Net Assets): ARKG, VTI, IWM, VXF, VB.
ADPT has underperformed the market in the last year with a price return of -31.3% while the SPY ETF gained +27.5%. However, in the short term, ADPT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +36.7% vs +4.0% return in SPY. But in the last 2 weeks, ADPT shares have been beat by the market, returning -4.0% compared to an SPY return of -0.2%.
ADPT support price is $4.41 and resistance is $4.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADPT stock will trade within this expected range on the day.